‘Human-on-a-chip’ Developments: A Translational Cutting-edge Alternative to Systemic Safety Assessment and Efficiency Evaluation of Substances in Laboratory Animals and Man?
Restricted accessResearch articleFirst published online October, 2012
‘Human-on-a-chip’ Developments: A Translational Cutting-edge Alternative to Systemic Safety Assessment and Efficiency Evaluation of Substances in Laboratory Animals and Man?
Various factors, including the phylogenetic distance between laboratory animals and humans, the discrepancy between current in vitro systems and the human body, and the restrictions of in silico modelling, have generated the need for new solutions to the ever-increasing worldwide dilemma of substance testing. This review provides a historical sketch on the accentuation of this dilemma, and highlights fundamental limitations to the countermeasures taken so far. It describes the potential of recently-introduced microsystems to emulate human organs in ‘organ-on-a-chip’ devices. Finally, it focuses on an in-depth analysis of the first devices that aimed to mimic human systemic organ interactions in ‘human-on-a-chip’ systems. Their potential to replace acute systemic toxicity testing in animals, and their inability to provide alternatives to repeated dose long-term testing, are discussed. Inspired by the latest discoveries in human biology, tissue engineering and microsystems technology, this review proposes a paradigm shift to overcome the apparent challenges. A roadmap is outlined to create a new homeostatic level of biology in ‘human-on-a-chip’ systems in order to, in the long run, replace systemic repeated dose safety evaluation and disease modelling in animals.
BinettiR., CostamagnaF.M., & MarcelloI. (2008). Exponential growth of new chemicals and evolution of information relevant to risk control. Annali dell'Istituto Superiore di Sanità44, 13–15.
2.
EgeghyP.P., JudsonR., GangwalS., MosherS., SmithD., VailJ., & Cohen HubalE.A. (2012). The exposure data landscape for manufactured chemicals. Science of the Total Environment414, 159–166.
3.
UN (2009). Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments. Pharmaceuticals. 14th edn, 94 pp. New York, NY, USA: United Nations, Department of Economic and Social Affairs.
4.
UN (2005). Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments. Pharmaceuticals. 12th edn, 598 pp. New York, USA: United Nations, Department of Economic and Social Affairs.
5.
RussellW.M.S., & BurchR.L. (1959). The Principles of Humane Experimental Technique, 238 pp. London, UK: Methuen.
6.
European Council (1986). Council Directive 86/609/EEC of November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European UnionL358, 18.12.1986, 1–28.
7.
European Parliament (2010). Directive 2010/63/ EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European UnionL276, 20.10.2010, 33–79.
8.
European Parliament (2003). Directive 2003/15/ EC of the European Parliament and of the Council of 27 February 2003 amending Council Directive 76/768/EEC on the approximation of the laws of the Member States relating to cosmetic products. Official Journal of the European UnionL66, 11.03.2003, 26–35.
9.
European Parliament (2006). Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/ EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Official Journal of the European UnionL396, 30.12.2006, 1–849.
10.
European Parliament (1999). Directive 1999/45/EC of the European Parliament and of the Council of 31 May 1999 concerning the approximation of the laws, regulations and administrative provisions of the Member States relating to the classification, packaging and labelling of dangerous preparations. Official Journal of the European UnionL200, 30.07.1999, 1–68.
11.
RovidaC., & HartungT. (2009). Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals — a report by the transatlantic think tank for toxicology (t(4)). ALTEX26, 187–208.
12.
BasketterD., CrozierJ., HubeschB., ManouI., MehlingA., & ScheelJ. (2012). Optimised testing strategies for skin sensitization — The LLNA and beyond. Regulatory Toxicology & Pharmacology64, 9–16.
13.
HartungT., BlaauboerB.J., BosgraS., CarneyE., CoenenJ., ConollyR.B., CorsiniE., GreenS., FaustmanE.M., GaspariA., HayashiM., Wallace HayesA., HengstlerJ.G., KnudsenL.E., KnudsenT.B., McKimJ.M., PfallerW., & RoggenE.L. (2011). An expert consortium review of the EC-commissioned report ‘Alternative (Non-Animal) methods for cosmetics testing: Current status and future prospects — 2010’. ALTEX28, 183–209.
14.
AdlerS., BasketterD., CretonS., PelkonenO., van BenthemJ., ZuangV., AndersenK.E., Angers-LoustauA., AptulaA., Bal-PriceA., BenfenatiE., BernauerU., BessemsJ., BoisF.Y., BoobisA., BrandonE., BremerS., BroschardT., CasatiS., CoeckeS., CorviR., CroninM., DastonG., DekantW., FelterS., GrignardE., Gundert-RemyU., HeinonenT., KimberI., KleinjansJ., KomulainenH., KreilingR., KreysaJ., LeiteS.B., LoizouG., MaxwellG., MazzatortaP., MunnS., PfuhlerS., PhrakonkhamP., PiersmaA., PothA., PrietoP., RepettoG., RogiersV., SchoetersG., SchwarzM., SerafimovaR., TähtiH., TestaiE., van DelftJ., van LoverenH., VinkenM., WorthA., & ZaldivarJ.M. (2011). Alternative (non-animal) methods for cosmetics testing: Current status and future prospects — 2010. Archives of Toxicology85, 367–485.
15.
KimberI., HumphrisC., WestmorelandC., AlepeeN., NegroG.D., & ManouI. (2011). Computational chemistry, systems biology and toxicology. Harnessing the chemistry of life: Revolutionizing toxicology. a commentary. Journal of Applied Toxicology31, 206–209.
16.
SeilerA.E.M., & SpielmannH. (2011). The validated embryonic stem cell test to predict embryotoxicity in vitro. Nature Protocols6, 961–978.
17.
GibbS. (2008). Toxicity testing in the 21st century: A vision and a strategy. Reproductive Toxicology25, 136–138.
18.
CollinsF.S., GrayG.M., & BucherJ.R. (2009). Transforming environmental health protection. Science, New York319, 906–907.
19.
KrewskiD., WestphalM., Al-ZoughoolM., CroteauM.C., & AndersenM.E. (2011). New directions in toxicity testing. Annual Review of Public Health32, 161–178.
20.
DixD.J., HouckK.A., MartinM.T., RichardA.M., SetzerR.W., & KavlockR.J. (2007). The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicological Sciences95, 5–12.
21.
ChiK.R. (2012). Stemming the toxic tide. The Scientist26, 1–6.
22.
RoepB.O., BucknerJ., SawcerS., ToesR., & ZippF. (2012). The problems and promises of research into human immunology and autoimmune disease. Nature Medicine18, 48–53.
23.
Kirsch-VoldersM., DecordierI., ElhajoujiA., PlasG., AardemaM.J., & FenechM. (2011). In vitro genotoxicity testing using the micronucleus assay in cell lines, human lymphocytes and 3D human skin models. Mutagenesis26, 177–184.
24.
Zeevi-LevinN., Itskovitz-EldorJ., & BinahO. (2012). Cardiomyocytes derived from human pluripotent stem cells for drug screening. Pharmacology & Therapeutics134, 180–188.
25.
AnkleyG.T., BennettR.S., EricksonR.J., HoffD.J., HornungM.W., JohnsonR.D., MountD.R., NicholsJ.W., RussomC.L., SchmiederP.K., SerrranoJ.A., TietgeJ.E., & VilleneuveD.L. (2010). Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environmental Toxicology & Chemistry/SETAC29, 730–741.
26.
WetmoreB., WambaughJ.F., FergusonS.S., SochaskiM.A., RotroffD.M., FreemanK., ClewellH.J.3rd, DixD.J., AndersenM.E., HouckK.A., AllenB., JudsonR.S., SinghR., KavlockR.J., RichardA.M., & ThomasR.S. (2012). Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicological Sciences125, 157–174.
27.
RotroffD.M., WetmoreB.A., DixD.J., FergusonS.S., ClewellH.J., HouckK.A., LecluyseE.L., AndersenM.E., JudsonR.S., SmithC.M., SochaskiM.A., KavlockR.J., BoellmannF., MartinM.T., ReifD.M., WambaughJ.F., & ThomasR.S. (2010). Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicological Sciences117, 348–358.
28.
HaysS.M., AylwardL.L., LaKindJ.S., BartelsM.J., BartonH.A., BoogaardP.J., BrunkC., DiZioS., DoursonM., GoldsteinD.A., LipscombJ., KilpatrickM.E., KrewskiD., KrishnanK., NordbergM., OkinoM., TanY.M., ViauC., YagerJ.W. & Biomonitoring Equivalents Expert Workshop (2008). Guidelines for the derivation of biomonitoring equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology & Pharmacology51, S4–S15.
29.
LaKindJ.S., AylwardL.L., BrunkC., DiZioS., DoursonM., GoldsteinD.A., KilpatrickM.E., KrewskiD., BartelsM.J., BartonH.A., BoogaardP.J., LipscombJ., KrishnanK., NordbergM., OkinoM., TanY.M., ViauC., YagerJ.W., HaysS.M. & Biomonitoring Equivalents Expert Workshop (2008). Guidelines for the communication of biomonitoring equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology & Pharmacology51, S16–S26.
30.
BhattacharyaS., ZhangQ., CarmichaelP.L., BoekelheideK., & AndersenM.E. (2011). Toxicity testing in the 21 century: Defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PloS One6, e20887.
31.
JudsonR.S., KavlockR.J., SetzerR.W., HubalE.A., MartinM.T., KnudsenT.B., HouckK.A., ThomasR.S., WetmoreB.A., & DixD.J. (2011). Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chemical Research in Toxicology24, 451–462.
32.
ClewellH.J., TanY.M., CampbellJ.L., & AndersenM.E. (2008). Quantitative interpretation of human biomonitoring data. Toxicology & Applied Pharmacology231, 122–133.
33.
ThomasR.S., BlackM.B., LiL., HealyE., ChuT.M., BaoW., AndersenM.E., & WolfingerR.D. (2012). A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicological Sciences128, 398–417.
34.
De BuckS.S., & MackieC.E. (2007). Physiologically based approaches towards the prediction of pharmacokinetics: In vitro–in vivo extrapolation. Expert Opinion on Drug Metabolism & Toxicology3, 865–878.
35.
CaldwellG.W., YanZ., TangW., DasguptaM., & HastingB. (2009). ADME optimization and toxicity assessment in early- and late-phase drug discovery. Current Topics in Medicinal Chemistry9, 965–980.
36.
McLimansW.F., BlumensonL.E., & TunnahK.V. (1968). Kinetics of gas diffusion in mammalian cell culture systems. II. Theory. Biotechnology & Bioengineering10, 741–763.
37.
KnazekR.A. (1972). Cell culture on artificial capillaries: An approach to tissue growth in vitro. Science178, 3–5.
38.
CatapanoG., & GerlachJ.C. (2007). Bioreactors for liver tissue engineering. Topics in Tissue Engineering3, 1–42.
39.
WangY., SusandoT., LeiX., Anene-NzeluC., ZhouH., LiangL.H., & YuH. (2010). Current development of bioreactors for extracorporeal bioartificial liver (Review). Biointerphases5, FA116–131.
40.
GieseC., DemmlerC.D., AmmerR., HartmannS., LubitzA., MillerL., MüllerR., MarxU. (2006). A human lymph node in vitro — challenges and progress. Artificial Organs30, 803–808.
41.
GieseC., LubitzA., DemmlerC.D., ReuschelJ., BergnerK., & MarxU. (2010). Immunological substance testing on human lymphatic micro-organoids in vitro. Journal of Biotechnology148, 38–45.
42.
PörtnerR., & GieseC. (2007). An overview on bioreactor design, prototyping and process control for reproducible three-dimensional tissue culture. In Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology (ed. MarxU., & SandigV.), pp. 53–78. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA.
43.
MarxU., & SandigV. (eds) (2007). Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology, 318 pp. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA.
44.
MarxU. (2012). Trends in cell culture technology. In New Technologies for Toxicity Testing (ed. BallsM., CombesR.D., & BhogalN.), pp. 26–46. Austin, TX, USA & New York, NY, USA: Landes Bioscience & Springer Science+Business Media, LLC.
45.
GriffithL.G., & SwartzM. (2006). Capturing complex 3D tissue physiology in vitro. Nature Reviews. Molecular Cell Biology7, 211–224.
46.
NelsonC.M., & GleghornJ.P. (2011). Sculpting organs: Mechanical regulation of tissue development. Annual Review of Biomedical Engineering14, 129–154.
47.
PeytonS.R., KalciogluZ.I., CohenJ.C., RunkleA.P., Van VlietK.J., LauffenburgerD.A., & GriffithL.G. (2011). Marrow-derived stem cell motility in 3D synthetic scaffold is governed by geometry along with adhesivity and stiffness. Biotechnology & Bioengineering108, 1181–1193.
AhadianS., Ramón-AzcónJ., OstrovidovS., Camci-UnalG., HosseiniV., KajiH., InoK., ShikuH., KhademhosseiniA., & MatsueT. (2012). Interdigitated array of Pt electrodes for electrical stimulation and engineering of aligned muscle tissue. Lab on a Chip12, 3491–3503.
50.
BussekA., WettwerE., ChristT., CamellitiP., & RavensU. (2009). Tissue slices from adult mammalian hearts as a model for pharmacological drug testing. Cellular Physiology Biochemistry & Biochemistry24, 527–536.
51.
JohnstoneA.F.M., GrossG.W., WeissD.G., SchroederO.H., GramowskiA., & ShaferT.J. (2010). Microelectrode arrays: A physiologically based neurotoxicity testing platform for the 21st century. Neurotoxicology31, 331–350.
52.
GramowskiA., JügeltK., SchröderO.H.U., WeissD. G., & MitznerS. (2011). Acute functional neurotoxicity of lanthanum(III) in primary cortical networks. Toxicological Sciences120, 173–83.
53.
HimmelH.M., BussekA., HoffmannM., BeckmannR., LohmannH., SchmidtM., & WettwerE. (2012). Field and action potential recordings in heart slices: Correlation with established in vitro and in vivo models. British Journal of Pharmacology166, 276–296.
54.
ParkT.H., & ShulerM.L. (2003). Integration of cell culture and microfabrication technology. Biotechnology Progress19, 243–253.
55.
AnderssonH., & van den BergA. (2004). Microfabrication and microfluidics for tissue engineering: State of the art and future opportunities. Lab on a Chip4, 98–103.
56.
KimL., TohY.C., VoldmanJ., & YuH. (2007). A practical guide to microfluidic perfusion culture of adherent mammalian cells. Lab on a Chip7, 681–694.
57.
WuM.H., HuangS.B., & LeeG.B. (2010). Microfluidic cell culture systems for drug research. Lab on a Chip10, 939–956.
58.
HuhD., HamiltonG., & IngberD.E. (2011). From 3D cell culture to organs-on-chips. Trends in Cell Biology21, 745–754.
59.
IngberD.E., & WhitesidesG.M. (2012). Lab on a chip: United States of America. Lab on a Chip12, 2089–2090.
60.
YoungE.W.K., & SimmonsC. (2010). Macro- and microscale fluid flow systems for endothelial cell biology. Lab on a Chip10, 143–160.
61.
GuW., ZhuX., FutaiN., ChoB.S., & TakayamaS. (2004). Computerized microfluidic cell culture using elastomeric channels and Braille displays. Proceedings of the National Academy of Sciences of the USA101, 15,861–15,866.
62.
LeclercE., SakaiY., & FujiiT. (2004). Microfluidic PDMS (polydimethylsiloxane) bioreactor for large-scale culture of hepatocytes. Biotechnology Progress20, 750–755.
63.
PowersM.J., DomanskyK., Kaazempur-MofradM.R., KaleziA., CapitanoA., UpadhyayaA., KurzawskiP., WackK.E., StolzD.B., KammR., & GriffithL.G. (2002). A microfabricated array bioreactor for perfused 3D liver culture. Biotechnology & Bioengineering78, 257–269.
64.
LeeP.J., HungP.J., & LeeL.P. (2007). An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnology & Bioengineering97, 1340–1346.
65.
TohY.C., ZhangC., ZhangJ., KhongY.M., ChangS., SamperV.D., van NoortD., HutmacherD.W., & YuH. (2007). A novel 3D mammalian cell perfusion-culture system in microfluidic channels. Lab on a Chip7, 302–309.
66.
TohY.C., LimT.C., TaiD., XiaoG., van NoortD., & YuH. (2009). A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab on a Chip9, 2026–2035.
67.
CarraroA., HsuW.M., KuligK.M., CheungW.S., MillerM.L., WeinbergE.J., SwartE.F., Kaazempur-MofradM., BorensteinJ.T., VacantiJ.P., & NevilleC. (2008). In vitro analysis of a hepatic device with intrinsic microvascular-based channels. Biomedical Microdevices10, 795–805.
68.
GoralV.N., HsiehY.C., PetzoldO.N., ClarkJ.S., YuenP.K., & FarisR.A. (2010). Perfusion-based microfluidic device for three-dimensional dynamic primary human hepatocyte cell culture in the absence of biological or synthetic matrices or coagulants. Lab on a Chip10, 3380–3386.
HoC.T., LinR.Z., ChangW.Y., ChangH., & LiuC.H. (2006). Rapid heterogeneous liver-cell on-chip patterning via the enhanced field-induced dielect-rophoresis trap. Lab on a Chip6, 724–734.
71.
RheeS.W., TaylorA.M., TuC.H., CribbsD.H., CotmanC.W., & JeonN.L. (2005). Patterned cell culture inside microfluidic devices. Lab on a Chip5, 102–107.
72.
GraftonM.M.G., WangL., VidiP.A., LearyJ., & LelièvreS. (2011). Breast on-a-chip: Mimicry of the channeling system of the breast for development of theranostics. Integrative Biology3, 451–459.
73.
NakayamaH., KimuraH., KomoriK., FujiiT., & SakaiY. (2008). Development of a disposable three-compartment micro-cell culture device for toxicokinetic study in humans and its preliminary evaluation. AATEX14, 619–622.
74.
HungP.J., LeeP.J., SabounchiP., AghdamN., LinR., & LeeL.P. (2005). A novel high aspect ratio microfluidic design to provide a stable and uniform microenvironment for cell growth in a high throughput mammalian cell culture array. Lab on a Chip5, 44–48.
75.
ChungB.G., FlanaganL.A., RheeS.W., SchwartzP.H., LeeA.P., MonukiE.S., & JeonN.L. (2005). Human neural stem cell growth and differentiation in a gradient-generating microfluidic device. Lab on a Chip5, 401–406.
76.
Villa-DiazL.G., TorisawaY.S., UchidaT., DingJ., Nogueira-de-SouzaN.C., O'SheaK.S., TakayamaS., & SmithG.D. (2009). Microfluidic culture of single human embryonic stem cell colonies. Lab on a Chip9, 1749–1755.
77.
SmithG.D., TakayamaS., & SwainJ.E. (2012). Rethinking in vitro embryo culture: New developments in culture platforms and potential to improve assisted reproductive technologies. Biology of Reproduction86, 62.
78.
HuhD., MatthewsB.D., MammotoA., Montoya-ZavalaM., HsinH.Y., & IngberD.E. (2010). Reconstituting organ-level lung functions on a chip. Science328, 1662–1668.
79.
KaneB.J., ZinnerM.J., YarmushM.L., & TonerM. (2006). Liver-specific functional studies in a microfluidic array of primary mammalian hepatocytes. Analytical Chemistry78, 4291–4298.
80.
HwaA.J., FryR.C., SivaramanA., SoP.T., SamsonL.D., StolzD.B., & GriffithL.G. (2007). Rat liver sinusoidal endothelial cells survive without exogenous VEGF in 3D perfused cocultures with hepatocytes. FASEB Journal21, 2564–2579.
81.
KhetaniS.R., & BhatiaS.N. (2008). Microscale culture of human liver cells for drug development. Nature Biotechnology26, 120–126.
82.
GüntherA., YasotharanS., VagaonA., LochovskyC., PintoS., YangJ., LauC., Voigtlaender-BolzJ., & BolzS.S. (2010). A microfluidic platform for probing small artery structure and function. Lab on a Chip10, 2341–2349.
83.
OotaniA., LiX., SangiorgiE., HoQ.T., UenoH., TodaS., SugiharaH., FujimotoK., WeissmanI.L., CapecchiM.R., & KuoC.J. (2010). Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nature Medicine15, 701–706.
84.
SatoT., VriesR.G., SnippertH.J., van de WeteringM., BarkerN., StangeD.E., van EsJ.H., AboA., KujalaP., PetersP.J., & CleversH. (2009). Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature, London459, 262–265.
85.
SungJ.H., YuJ., LuoD., ShulerM.L., & MarchJ.C. (2011). Microscale 3-D hydrogel scaffold for biomimetic gastrointestinal (GI) tract model. Lab on a Chip11, 389–392.
86.
LaharN., LeiN.Y., WangJ., JabajiZ., TungS.C., JoshiV., LewisM., StelznerM., MartínM.G., & DunnJ.C.Y. (2011). Intestinal subepithelial myofibroblasts support in vitro and in vivo growth of human small intestinal epithelium. PloS One6, e26898.
87.
YuJ., PengS., LuoD., & MarchJ.C. (2012). In vitro 3D human small intestinal villous model for drug permeability determination. Biotechnology & Bioengineering109, 2173–2178.
88.
ParkJ.Y., HwangC.M., & LeeS.H. (2009). Ice-lithographic fabrication of concave microwells and a microfluidic network. Biomedical Microdevices11, 129–33.
89.
CuiZ.F., XuX., TrainorN., TriffittJ.T., UrbanJ.P., & TirlapurU.K. (2007). Application of multiple parallel perfused microbioreactors and three-dimensional stem cell culture for toxicity testing. Toxicology in Vitro21, 1318–1324.
90.
van MidwoudP.M., MeremaM.T., VerpoorteE., & GroothuisG.M.M. (2010). A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. Lab on a Chip10, 2778–2786.
91.
LeclercE., BaudoinR., CorluA., GriscomL., Luc DuvalJ., & LegallaisC. (2007). Selective control of liver and kidney cells migration during organotypic cocultures inside fibronectin-coated rectangular silicone microchannels. Biomaterials28, 1820–1829.
92.
GuzzardiM.A., VozziF., & AhluwaliaA.D. (2009). Study of the crosstalk between hepatocytes and endothelial cells using a novel multicompartmental bioreactor: A comparison between connected cultures and cocultures. Tissue Engineering: Part A15, 3635–3644.
93.
VozziF., HeinrichJ., BaderA., & AhluwaliaA.D. (2009). Connected culture of murine hepatocytes and human umbilical vein endothelial cells in a multicompartmental bioreactor. Tissue Engineering: Part A15, 1291–1299.
94.
PilarekM., NeubauerP., & MarxU. (2011). Biological cardio-micro-pumps for microbioreactors and analytical microsystems. Sensors & Actuators B: Chemical156, 517–526.
95.
DashA., InmanW., HoffmasterK., SevidalS., KellyJ., ObachR.S., GriffithL.G., & TannenbaumS.R. (2009). Liver tissue engineering in the evaluation of drug safety. Expert Opinion on Drug Metabolism & Toxicology5, 1159–1174.
96.
SchaeferC., SpielmannH., & VetterK. (eds.) (2006). Arzneiverordnung in Schwangerschaft und Stillzeit, 785 pp. München, Germany: Elsevier GmbH and Urban & Fischer Verlag.
97.
SweeneyL.M., ShulerM.L., BabishJ.G., & GhanemA. (1995). A cell culture analogue of rodent physiology: Application to naphthalene toxicology. Toxicology in Vitro9, 307–316.
98.
SinA., ChinK.C., JamilM.F., KostovY., RaoG., & ShulerM.L. (2004). The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnology Progress20, 338–345.
99.
SungJ.H., & ShulerM.L. (2010). In vitro microscale systems for systematic drug toxicity study. Bioprocess & Biosystems Engineering33, 5–19.
100.
ShulerM.L. (2012). Modeling life. Annals of Biomedical Engineering40, 1399–1407.
101.
ViravaidyaK., SinA., & ShulerM.L. (2004). Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnology Progress20, 316–323.
102.
TatosianD., & ShulerM.L. (2009). A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers. Biotechnology & Bioengineering103, 187–198.
103.
SungJ.H., & ShulerM.L. (2009). A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab on a Chip9, 1385–1394.
104.
SungJ.H., KamC., & ShulerM.L. (2010). A microfluidic device for a pharmacokinetic-pharma-codynamic (PK-PD) model on a chip. Lab on a Chip10, 446–455.
105.
MahlerG.J., EschM.B., GlahnR.P., & ShulerM.L. (2009). Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity. Biotechnology & Bioengineering104, 193–205.
106.
MahlerG.J., ShulerM.L., & GlahnR.P. (2009). Characterization of Caco-2 and HT29-MTX cocultures in an in vitro digestion/cell culture model used to predict iron bioavailability. Journal of Nutritional Biochemistry20, 494–502.
107.
MahlerG.J., EschM.B., TakoE., SouthardT.L., ArcherS.D., GlahnR.P., & ShulerM.L. (2012). Oral exposure to polystyrene nanoparticles affects iron absorption. Nature Nanotechnology7, 264–271.
108.
ZhangC., ZhaoZ., Abdul RahimN.A., van NoortD., & YuH. (2009). Towards a human-on-chip: Culturing multiple cell types on a chip with compartmentalized microenvironments. Lab on a Chip9, 3185–3192.
109.
ImuraY., SatoK., & YoshimuraE. (2010). Micro total bioassay system for ingested substances: Assessment of intestinal absorption, hepatic metabolism, and bioactivity. Analytical Chemistry82, 9983–9988.
110.
SonntagF., SchillingN., MaderK., GruchowM., KlotzbachU., LindnerG., HorlandR., WagnerI., LausterR., HowitzS., HoffmannS., & MarxU. (2010). Design and prototyping of a chip-based multi-micro-organoid culture system for substance testing, predictive to human (substance) exposure. Journal of Biotechnology148, 70–75.
111.
WuM.H., HuangS.B., CuiZ., CuiZ., & LeeG.B. (2008). A high throughput perfusion-based micro-bioreactor platform integrated with pneumatic micropumps for three-dimensional cell culture. Biomedical Microdevices10, 309–319.
BakerM. (2011). Künstliches Organ statt Tierexperiment. Spektrum der Wissenschaft10, 12–15.
114.
LiaoK.H., TanY.M., & ClewellH.J. (2007). Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: Reverse dosimetry on biomonitoring data for trichloroethylene. Risk Analysis27, 1223–1236.
115.
ClewellH.J., GearhartJ.M., GentryP.R., CovingtonT.R., VanLandinghamC.B., CrumpK.S., & ShippA.M. (1999). Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Analysis19, 547–558.
116.
LarrivéeB., FreitasC., SuchtingS., BrunetI., & EichmannA. (2009). Guidance of vascular development: Lessons from the nervous system. Circulation Research104, 428–441.
117.
TamS.J., & WattsR.J. (2010). Connecting vascular and nervous system development: Angiogenesis and the blood–brain barrier. Annual Review of Neuroscience33, 379–408.
118.
QuaegebeurA., LangeC., & CarmelietP. (2011). The neurovascular link in health and disease: Molecular mechanisms and therapeutic implications. Neuron71, 406–424.
119.
PugsleyM.K., & TabrizchiR. (2001). The vascular system. An overview of structure and function. Journal of Pharmacological & Toxicological Methods44, 333–340.
120.
AirdW.C. (2007). Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circulation Research100, 158–173.
121.
SarinH. (2010). Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. Journal of Angiogenesis Research2, 14.
122.
RivronN.C., RaissC.C., LiuJ., NandakumarA., StichtC., GretzN., TruckenmüllerR., RouwkemaJ., & van BlitterswijkC.A. (2012). Sonic Hedgehog-activated engineered blood vessels enhance bone tissue formation. Proceedings of the National Academy of Sciences of the USA109, 4413–4418.
123.
LuuN.T., RahmanM., StoneP.C., RaingerG.E., & NashG.B. (2010). Responses of endothelial cells from different vessels to inflammatory cytokines and shear stress: Evidence for the pliability of endothelial phenotype. Journal of Vascular Research47, 451–461.
LiekensS., De ClercqE., & NeytsJ. (2001). Angiogenesis: Regulators and clinical applications. Biochemical Pharmacology61, 253–270.
126.
AdamsR.H., & AlitaloK. (2007). Molecular regulation of angiogenesis and lymphangiogenesis. Nature Reviews. Molecular Cell Biology8, 464–478.
127.
Iruela-ArispeM.L., & DavisG.E. (2009). Cellular and molecular mechanisms of vascular lumen formation. Developmental Cell16, 222–231.
128.
LazarusA., Del-MoralP.M., IlovichO., MishaniE., WarburtonD., & KeshetE. (2011). A perfusion-independent role of blood vessels in determining branching stereotypy of lung airways. Development138, 2359–2368.
129.
HerbertS.P., & StainierD.Y.R. (2011). Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nature Reviews. Molecular Cell Biology12, 551–564.
130.
CarmelietP., & JainR.K. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature, London473, 298–307.
131.
DavisG.E., StratmanA.N., SacharidouA., & KohW. (2011). Molecular basis for endothelial lumen formation and tubulogenesis during vascu-logenesis and angiogenic sprouting. International Review of Cell & Molecular Biology288, 101–165.
132.
SudoR., ChungS., ZervantonakisI.K., VickermanV., ToshimitsuY., GriffithL.G., & KammR.D. (2009). Transport-mediated angiogenesis in 3D epithelial coculture. FASEB Journal23, 2155–2164.
133.
DaleyW.P., PetersS.B., & LarsenM. (2008). Extracellular matrix dynamics in development and regenerative medicine. Journal of Cell Science121, 255–264.
134.
LuP., & WerbZ. (2008). Patterning mechanisms of branched organs. Science, New York322, 1506–1509.
135.
SlackJ.M.W. (2008). Origin of stem cells in organogenesis. Science, New York322, 1498–1501.
136.
ZaretK.S., & GrompeM. (2008). Generation and regeneration of cells of the liver and pancreas. Science, New York322, 1490–1494.
137.
FrantzC., StewartK.M., & WeaverV.M. (2010). The extracellular matrix at a glance. Journal of Cell Science123, 4195–4200.
138.
FantinA., VieiraJ.M., GestriG., DentiL., SchwarzQ., PrykhozhijS., PeriF., WilsonS.W., & RuhrbergC. (2010). Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood116, 829–840.
139.
LuP., TakaiK., WeaverV.M., & WerbZ. (2011). Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harbor Perspectives in Biology3, 1–24.
140.
BadylakS.F., TaylorD., & UygunK. (2011). Whole-organ tissue engineering: Decellularization and recellularization of three-dimensional matrix scaffolds. Annual Review of Biomedical Engineering13, 27–53.
141.
RustadK.C., SorkinM., LeviB., LongakerM.T., & GurtnerG.C. (2010). Strategies for organ level tissue engineering. Organogenesis6, 151–157.
142.
WallesT., BiancosinoC., ZardoP., GottliebJ., & MertschingH. (2005). Tissue remodeling in a bio-artifical fibromuscular patch following transplantation in a human. Transplantation80, 284–285.
143.
MertschingH., SchanzJ., StegerV., SchandarM., SchenkM., HansmannJ., DallyI., FriedelG., & WallesT. (2009). Generation and transplantation of an autologous vascularized bioartificial human tissue. Transplantation88, 203–210.
144.
MertschingH., WallesT., HofmannM., SchanzJ., & KnappW.H. (2005). Engineering of a vascularized scaffold for artificial tissue and organ generation. Biomaterials26, 6610–6617.
145.
RivronN.C., VrijE.J., RouwkemaJ.L.S., & BergA.V.D. (2012). Tissue deformation spatially modulates VEGF signaling and angiogenesis. Proceedings of the National Academy of Sciences of the USA109, 6886–6891.
146.
SchanzJ., PuschJ., HansmannJ., & WallesH. (2010). Vascularised human tissue models: A new approach for the refinement of biomedical research. Journal of Biotechnology148, 56–63.
147.
MillerJ.S., StevensK.R., YangM.T., BakerB. M., NguyenD.H., CohenD.M., ToroE., ChenA.A., GalieP.A., YuX., ChaturvediR., BhatiaS.N., & ChenC.S. (2012). Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nature Materials11, 1–7.
ZornA.M., & WellsJ.M. (2009). Vertebrate endo-derm development and organ formation. Annual Review of Cell & Developmental Biology25, 221–251.
150.
LindnerG., HorlandR., WagnerI., AtaçB., & LausterR. (2011). De novo formation and ultrastructural characterization of a fiber-producing human hair follicle equivalent in vitro. Journal of Biotechnology152, 108–112.
151.
Preynat-SeauveO., SuterD.M., TirefortD., TurchiL., VirolleT., ChneiweissH., FotiM., LobrinusJ.A., StoppiniL., FekiA., Dubois-DauphinM., & KrauseK.H. (2009). Development of human nervous tissue upon differentiation of embryonic stem cells in three-dimensional culture. Stem Cells27, 509–520.
152.
McCrackenK.W., HowellJ.C., WellsJ.M., & SpenceJ.R. (2011). Generating human intestinal tissue from pluripotent stem cells in vitro. Nature Protocols6, 1920–1928.
153.
SpenceJ.R., MayhewC.N., RankinS.A., KuharM.F., VallanceJ.E., TolleK., HoskinsE.E., KalinichenkoV.V., WellsS.I., ZornA.M., ShroyerN.F., & WellsJ.M. (2011). Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature, London470, 105–109.
154.
ScaddenD.T. (2006). The stem-cell niche as an entity of action. Nature, London441, 1075–1079.
155.
LindvallO., KokaiaZ., & RandoT. (2006). Stem cells, ageing and the quest for immortality. Nature, London441, 1080–1086.
156.
JonesD.L., & WagersA.J. (2008). No place like home: Anatomy and function of the stem cell niche. Nature Reviews. Molecular Cell Biology9, 11–21.
157.
SigalS.H., BrillS., FiorinoS., & ReidL.M. (1992). The liver as a stem cell and lineage system. American Journal of Physiology263, G139–G148.
158.
OhS., HatchH.M., & PetersenB.E. (2002). Hepatic oval ‘stem’ cell in liver regeneration. Seminars in Cells & Developmental Biology13, 405–409.
159.
KloepperJ.E., TiedeS., BrinckmannJ., ReinhardtD.P., MeyerW., FaesslerR., & PausR. (2008). Immunophenotyping of the human bulge region: The quest to define useful in situ markers for human epithelial hair follicle stem cells and their niche. Experimental Dermatology17, 592–609.
160.
WalkerM.R., & StappenbeckT.S. (2008). Deciphering the ‘black box’ of the intestinal stem cell niche: Taking direction from other systems. Current Opinion in Gastroenterology24, 115–120.
161.
KimC.F. (2007). Paving the road for lung stem cell biology: Bronchioalveolar stem cells and other putative distal lung stem cells. American Journal of Physiology. Lung Cellular & Molecular Physiology293, L1092–L1098.
162.
YinT., & LiL. (2006). The stem cell niches in bone. Journal of Clinical Investigation116, 1195–1201.
163.
Martinez-AgostoJ., MikkolaH.K., HartensteinV., & BanerjeeU. (2007). The hematopoietic stem cell and its niche: A comparative view. Genes & Development21, 3044–3060.
164.
CanA. (2008). Haematopoietic stem cells niches: Interrelations between structure and function. Transfusion & Apheresis Science38, 261–268.
165.
RiquelmeP., DrapeauE., & DoetschF. (2008). Brain micro-ecologies: Neural stem cell niches in the adult mammalian brain. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences363, 123–137.
166.
MorganJ.E., & PartridgeT. (2003). Muscle satellite cells. International Journal of Biochemistry & Cell Biology35, 1151–1156.
167.
LeriA., KajsturaJ.A.N., & AnversaP. (2005). Cardiac stem cells and mechanisms of myocardial regeneration. Physiology Reviews85, 1373–1416.
168.
ChafferC.L., ThompsonE.W., & WilliamsE.D. (2007). Mesenchymal to epithelial transition in development and disease. Cells, Tissues, Organs185, 7–19.
169.
BryantD.M., & MostovK.E. (2010). From cells to organs: Building polarized tissue. Nature Reviews. Molecular Cell Biology9, 887–901.
170.
ThieryJ.P., AcloqueH., HuangR.Y.J., & NietoM.A. (2009). Epithelial–mesenchymal transitions in development and disease. Cell139, 871–890.
171.
NietoM.A. (2011). The ins and outs of the epithelial to mesenchymal transition in health and disease. Annual Review of Cell & Developmental Biology27, 347–376.
172.
DellianM., HelmlingerG., YuanF., & JainR.K. (1996). Fluorescence ratio imaging of interstitial pH in solid tumours: Effect of glucose on spatial and temporal gradients. British Journal of Cancer74, 1206–1215.
173.
KhaustovaS., ShkurnikovM., TonevitskyE., ArtyushenkoV., & TonevitskyA. (2010). Noninvasive biochemical monitoring of physiological stress by Fourier transform infrared saliva spectroscopy. The Analyst135, 3183–3192.
174.
SakharovD.A., MaltsevaD.V., RiabenkoE.A., ShkurnikovM.U., NorthoffH., TonevitskyA.G., & GrigorievA.I. (2012). Passing the anaerobic threshold is associated with substantial changes in the gene expression profile in white blood cells. European Journal of Applied Physiology112, 963–972.
175.
FabroS., SchumacherH., SmithR.L., StaggR.B., & WilliamsR.T. (1965). The metabolism of thalidomide: Some biological effects of thalidomide and its metabolites. British Journal of Pharmacology & Chemotherapy25, 352–362.
176.
WoollamD.H. (1965). Principles of teratogenesis: Mode of action of thalidomide. Proceedings of the Royal Society of Medicine58, 497–501.
177.
BauerK.S., DixonS.C., & FiggW.D. (1998). Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochemical Pharmacology55, 1827–1834.
SolomonG.M., & SchettlerT. (2000). Environment and health: 6. Endocrine disruption and potential human health implications. Canadian Medical Association Journal163, 1471–1476.
180.
BasseinE. (2004). DDT as an Endocrine Disruptor in Human and Nonhuman Test Cases, 5 pp. Boston, MA, USA: MIT OpenCourseWare.
181.
HardingA.K., DastonG.P., BoydG.R., LucierG.W., SafeS.H., StewartJ., TillittD.E., & Van Der KraakG. (2006). Endocrine disrupting chemicals research program of the US Environmental Protection Agency: Summary of a peer-review report. Environmental Health Perspectives114, 1276–1282.
182.
PatisaulH.B., & AdewaleH.B. (2009). Long-term effects of environmental endocrine disruptors on reproductive physiology and behavior. Frontiers in Behavioral Neuroscience3, 10.
